865200-20-0
Chemical Structure
Giripladib
Synonym(s): PLA-695
- CAS No.: 865200-20-0
- Formula:C41H36ClF3N2O4S
- Molecular Weight:745.25
IUPAC Name: 4-(3-(1-benzhydryl-5-chloro-2-(2-(((2-(trifluoromethyl)phenyl)methyl)sulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid
InChIKey: NHHBNHIPCSPSHQ-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(CCCC2=C(CCNS(=O)(CC3=C(C(F)(F)F)C=CC=C3)=O)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=C2C=C(C=C6)Cl)C=C1)O
Biological Activity: Giripladib (PLA-695) is a selective cPLA2α inhibitor. Giripladib attenuates CKD serum-induced PUFA accumulation, MDA and ROS levels, restores the GSH/GSSG ratio, and alleviates mitochondria-Ferroptosis-related morphological changes. Giripladib exhibits anti-inflammatory and disease-modifying effects in collagen-induced arthritis. Giripladib can be used in research on chronic kidney disease-associated plaque vulnerability, rheumatoid arthritis, and breast cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Giripladib | 99.68% | Giripladib (PLA-695) is a selective cPLA2α inhibitor. Giripladib attenuates CKD serum-induced PUFA accumulation, MDA and ROS levels, restores the GSH/GSSG ratio, and alleviates mitochondria-Ferroptosis-related morphological changes. Giripladib exhibits anti-inflammatory and disease-modifying effects in collagen-induced arthritis. Giripladib can be used in research on chronic kidney disease-associated plaque vulnerability, rheumatoid arthritis, and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bi X, et al. -Deficiency-Mediated Polyunsaturated Fatty Acid Accumulation Promotes Vascular Smooth Muscle Cell Ferroptosis and Chronic-Kidney-Disease-Associated Plaque Vulnerability. Research (Washington, D.C.). 2026;9:1411.
- [2]. Mitchener MM, et al. Competition and allostery govern substrate selectivity of cyclooxygenase-2. Proceedings of the National Academy of Sciences of the United States of America. 2015 Oct 06;112(40):12366-71.
- [3]. Kokotos G, et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. Journal of medicinal chemistry. 2014 Sep 25;57(18):7523-35. [Content Brief]
- [4]. Liu S, et al. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. Journal of hematology & oncology. 2021 Oct 29;14(1):178. [Content Brief]
